News
HOWL
0.9466
-3.97%
-0.0391
Weekly Report: what happened at HOWL last week (1109-1113)?
Weekly Report · 4d ago
Werewolf Therapeutics, Inc. Announces Clinical Data for WTX-124 and WTX-330
NASDAQ · 11/09 21:22
Werewolf Therapeutics Reports Positive WTX-124 and WTX-330 Clinical Data
TipRanks · 11/09 14:48
Werewolf Therapeutics announces new clinical data from WTX-124 trial
TipRanks · 11/09 14:18
Weekly Report: what happened at HOWL last week (1102-1106)?
Weekly Report · 11/09 09:43
Weekly Report: what happened at HOWL last week (1026-1030)?
Weekly Report · 11/02 09:42
Werewolf Therapeutics To Present Two Posters On WTX-124, WTX-330 Data At Upcoming SITC 2026 Annual Meeting
Benzinga · 10/30 12:33
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 10/27 21:05
Weekly Report: what happened at HOWL last week (1019-1023)?
Weekly Report · 10/26 09:42
Weekly Report: what happened at HOWL last week (1012-1016)?
Weekly Report · 10/19 09:42
Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why
NASDAQ · 10/13 15:00
Weekly Report: what happened at HOWL last week (1005-1009)?
Weekly Report · 10/12 09:45
New Strong Buy Stocks for October 9th
NASDAQ · 10/09 09:46
Weekly Report: what happened at HOWL last week (0928-1002)?
Weekly Report · 10/05 09:45
Weekly Report: what happened at HOWL last week (0921-0925)?
Weekly Report · 09/28 09:42
Weekly Report: what happened at HOWL last week (0914-0918)?
Weekly Report · 09/21 09:42
Weekly Report: what happened at HOWL last week (0907-0911)?
Weekly Report · 09/14 09:45
Weekly Report: what happened at HOWL last week (0831-0904)?
Weekly Report · 09/07 09:42
Weekly Report: what happened at HOWL last week (0824-0828)?
Weekly Report · 08/31 09:45
Werewolf Therapeutics Completes Key Early Trial For WTX-124 In Hard-To-Treat Cancers
TipRanks · 08/27 16:30
More
Webull provides a variety of real-time HOWL stock news. You can receive the latest news about Werewolf Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About HOWL
Werewolf Therapeutics, Inc. is a biopharmaceutical company engaged in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s advanced clinical-stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. It is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. It is advancing WTX-712, WTX-518, and WTX-921 through preclinical development.